BRKR Bruker Corporation

Bruker Corporation (NASDAQ: BRKR) today reported its financial results for the three and six months ended June 30, 2008. On February 26, 2008, Bruker BioSciences Corporation closed its acquisition of the Bruker BioSpin Group, and renamed itself Bruker Corporation. Under US GAAP, this transaction is accounted for as an acquisition of businesses under common control, and as a result all one-time transaction costs are expensed in the period in which they are incurred, rather than being added to goodwill. In addition, expenses incurred subsequent to the consummation of the acquisition, such as interest expenses incurred on acquisition related debt, are not reflected in the financial results of periods prior to the date of the acquisition, as they typically would be in pro-forma financials in acquisitions of unrelated parties. After the closing of the transaction all historical financial statements are required to be restated by combining the historical consolidated financial statements of Bruker BioSciences Corporation with those of the Bruker BioSpin Group. Accordingly, the financial results for the three and six months ended June 30, 2008 and 2007, included within this release, represent the combined historical consolidated financial statements of Bruker BioSciences Corporation with those of the Bruker BioSpin Group. Financial Results In the second quarter of 2008, revenue increased 31% to $311.5 million, compared to revenue of $238.3 million in the second quarter of 2007. Excluding the effects of foreign currency translation, second quarter 2008 revenue increased by 19% year-over-year. Net income in the second quarter of 2008 was $21.7 million, or $0.13 per diluted share, compared to net income of $17.7 million, or $0.11 per diluted share, in the second quarter of 2007. Included in net income for the second quarter of 2008 were after-tax charges of $0.3 million, or $0.00 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group. For the six months ended June 30, 2008, revenue increased 23% to $549.9 million, compared to revenue of $445.9 million during the six months ended June 30, 2007. Excluding the effects of foreign currency translation, revenue for the six months ended June 30, 2008 increased by 13% year-over-year. Net income during the six months ended June 30, 2008 was $21.0 million, or $0.13 per diluted share, compared to net income of $32.0 million, or $0.20 per diluted share, during the six months ended June 30, 2007. Included in GAAP EPS for the six months ended June 30, 2008 were Bruker BioSpin acquisition related expenses of ($0.04) per diluted share, foreign exchange losses of ($0.04) per diluted share, and interest expense on acquisition related debt of ($0.03) per diluted share, with a cumulative effect of ($0.11) per diluted share. For comparison, included in net income for the six months ended June 30, 2007 were foreign exchange gains of $0.4 million, or $0.00 per diluted share, and there were no acquisition related charges or acquisition related interest expense. During the second quarter of 2008, Bruker repaid $158 million of acquisition related debt. As of June 30, 2008, Bruker Corporation had a net debt position of $110.4 million. Frank Laukien, President and Chief Executive Officer of Bruker Corporation, commented:��For the second quarter of 2008, we are very pleased with our strong revenue growth, as well as our sequential and year-over-year improvements in net income and EPS. In the first two quarters of 2008 we experienced significant quarterly fluctuations in our growth rates and margins, and we expect these fluctuations to continue going forward. In the first half of 2008, while our GAAP operating income grew by 7%, our adjusted operating income, which excludes expenses related to the acquisition of Bruker BioSpin, grew 22%. However, our adjusted operating margin as a percentage of revenue was essentially flat, and therefore, in the third quarter of 2008, we intend to reaccelerate our gross margin improvement programs and to implement various streamlining and expense cutting steps with the objective of obtaining better margin leverage from our top-line growth.� Bill Knight, Bruker�s Chief Financial Officer, concluded: �While the present global market environment is more challenging than a year ago, we are optimistic that our various medium-term growth and margin initiatives will continue our positive profitability trends of the last three years. Our goal remains to drive our margins towards and beyond industry standards, while maintaining rapid revenue growth.� USE OF NON-GAAP FINANCIAL MEASURES In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted operating income, adjusted operating margin and adjusted EPS. Adjusted operating income and margin excludes acquisition related charges and adjusted EPS excludes acquisition related charges, interest expense on acquisition related debt, and foreign exchange gains and losses. We believe the inclusion of these non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company�s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results prepared in accordance with GAAP. EARNINGS CONFERENCE CALL Bruker Corporation will host an operator-assisted earnings conference call at 9 a.m. Eastern Daylight Time on Thursday, July 31, 2008. To listen to the webcast, investors can go to www.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone by calling 888-339-2688, or +1-617-847-3007 outside the US and Canada. Investors should refer to the Bruker Corporation Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 76210411. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2007, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law. Bruker Corporation CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) � � � � Three Months Ended June 30, Six Months Ended June 30, � 2008 � 2007 � 2008 � � 2007 � Product revenue $ 278,849 $ 210,177 $ 485,884 $ 391,786 Service revenue 31,733 27,570 61,690 52,757 Other revenue � 883 � 595 � 2,327 � � 1,335 Total revenue 311,465 238,342 549,901 445,878 � Cost of product revenue 161,931 120,810 266,832 217,459 Cost of service revenue � 20,896 � 17,617 � 41,302 � � 33,956 Total cost of revenue � 182,827 � 138,427 � 308,134 � � 251,415 � Gross profit margin 128,638 99,915 241,767 194,463 � Operating Expenses: Sales and marketing 46,151 37,029 89,544 72,491 General and administrative 17,178 13,442 33,982 26,855 Research and development 36,514 27,657 67,719 53,621 Acquisition related charges � 360 � - � 6,153 � � - Total operating expenses � 100,203 � 78,128 � 197,398 � � 152,967 � Operating income 28,435 21,787 44,369 41,496 � Foreign exchange gains (losses), net 3,263 1,163 (8,956 ) 452 Interest and other income (expense), net � 264 � 1,051 � 294 � � 2,512 � Income before income tax provision and minority interest in consolidated subsidiaries 31,962 24,001 35,707 44,460 Income tax provision � 10,196 � 6,284 � 14,466 � � 12,307 � Income before minority interest in consolidated subsidiaries 21,766 17,717 21,241 32,153 Minority interest in consolidated subsidiaries � 80 � 60 � 240 � � 146 Net income $ 21,686 $ 17,657 $ 21,001 � $ 32,007 � Net income per share: Basic $ 0.13 $ 0.11 $ 0.13 � $ 0.20 Diluted $ 0.13 $ 0.11 $ 0.13 � $ 0.20 � Weighted average shares outstanding: Basic � 162,440 � 161,728 � 162,371 � � 161,050 Diluted � 165,438 � 164,343 � 165,308 � � 163,731 Bruker Corporation CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) � � June 30, December 31, � 2008 � 2007 � � ASSETS � Current assets: Cash and short-term investments $ 131,790 $ 344,554 Accounts receivable, net 164,236 185,217 Inventories 487,503 447,688 Other current assets � 75,697 � 57,238 Total current assets 859,226 1,034,697 � Property and equipment, net 236,321 207,588 Intangible and other assets � 75,895 � 69,346 � Total assets $ 1,171,442 $ 1,311,631 � LIABILITIES AND SHAREHOLDERS' EQUITY � Current liabilities: Short-term borrowings $ 63,754 $ 35,591 Accounts payable 54,288 52,293 Customer deposits 220,254 233,466 Other current liabilities � 235,455 � 239,841 Total current liabilities 573,751 561,191 � Long-term debt 178,396 8,605 Other long-term liabilities 109,713 105,445 Minority interest in subsidiaries 753 538 � Total shareholders' equity � 308,829 � 635,852 � Total liabilities and shareholders' equity $ 1,171,442 $ 1,311,631